[{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase IV","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Green Valley Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase IV","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Green Valley Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase IV","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Green Valley Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase IV","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Green Valley Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase IV","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Green Valley Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GV-971","moa":"Amyloid beta A4 protein (APP)","graph1":"Neurology","graph2":"Phase IV","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Valley Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Green Valley Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GV-971","moa":"Amyloid beta A4 protein (APP)","graph1":"Neurology","graph2":"Phase IV","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Valley Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Green Valley Pharmaceuticals \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Green Valley Pharmaceuticals
Details :
GV-971 (sodium oligomannate), demonstrated significant efficacy in improving cognition with sustained improvement across all observation periods of a 36-week trial. GV-971 was safe and well-tolerated.
Details :
Green Valley Pharma’s scientists have suggested that GV-971 may work by altering the balance of microorganisms in the GI tract that contribute to inflammation in the central nervous system.
Details :
Green Valley’s treatment, known as GV-971, relies on a type of sugar extracted from brown algae. The drug aims to treat imbalances in the microbiome of the gut, which researchers believe may cause inflammation in the brain and may lead to Alzheimer’s...